Paid COPD Clinical Trials
COPD clinical trials actively recruiting. Access new bronchodilators and anti-inflammatory treatments. Compensation up to $3,000 for qualifying participants.
Compensation
$1,500 - $3,000
Duration
24-52 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 40-80 years
- COPD diagnosis with post-bronchodilator FEV1/FVC < 0.70
- FEV1 30-80% predicted (moderate to severe)
- Current or former smoker (≥10 pack-years)
- At least one moderate exacerbation in past year
- Stable on current COPD medications for 4+ weeks
Who May Not Qualify
- Current diagnosis of asthma
- COPD exacerbation within 4 weeks of screening
- Long-term oxygen therapy >15 hours/day
- Lung cancer or lung volume reduction surgery
- Alpha-1 antitrypsin deficiency
Frequently Asked Questions
What COPD treatments are being studied?
+
Studies are investigating new triple therapy inhalers, biologics for eosinophilic COPD, novel anti-inflammatory agents, and regenerative approaches. Research also focuses on reducing exacerbations.
How are lung function tests performed?
+
Spirometry (breathing tests) are performed at most study visits to measure lung function. These non-invasive tests take about 15-30 minutes and involve breathing into a machine.
Can I continue using my inhalers?
+
Most studies allow continuation of certain background inhalers, though specific requirements vary. Rescue inhalers (short-acting bronchodilators) are typically permitted throughout.
What if I have an exacerbation during the study?
+
Exacerbations are managed according to standard care (typically with steroids and/or antibiotics). These events are tracked as important study outcomes but do not necessarily end your participation.